Chemotherapy News and Research

Latest Chemotherapy News and Research

Colon cancer screenings recommended at 45 for African Americans

According to the American Cancer Society, there were about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer in 2008. Overall, the two cancers caused nearly 50,000 deaths last year.

16 Mar 2009

Blocking the dual leucine zipper kinase gene may help ease painful nerve condition

Scientists have identified the first gene that pulls the plug on ailing nerve cell branches from within the nerve cell, possibly helping to trigger the painful condition known as neuropathy.

15 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

Oncolytics Biotech Inc. has announced that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours.

12 Mar 2009

Rituximab may be effective in treating membranous nephropathy

Current treatments for membranous nephropathy are limited to steroids, calcineurin inhibitors, and chemotherapeutic agents, all of which have significant side effects.

11 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Twin nanoparticle targets then zaps breast cancer cells

Breast cancer patients face many horrors, including those that arise when fighting the cancer itself.

11 Mar 2009

Researchers create gene circuit that permits precise tuning of a gene's expression in a cell

Researchers have crafted a gene circuit that permits precise tuning of a gene's expression in a cell, an advance that should allow for more accurate analysis of the gene's role in normal and abnormal cellular function.

11 Mar 2009

Rituximab useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

11 Mar 2009

SOX9 protein may be a potential target for melanoma treatment

In a new study released today, researchers have shown that a specific protein plays an important role in inhibiting the development and spread of melanoma tumors in mouse and in human skin models.

11 Mar 2009

Immune-based therapy approved in Europe for pediatric cancer patients

The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.

11 Mar 2009

First 'nano' treatments to target cancer cells

Cancer Research UK scientists have for the first time developed a treatment that transports 'tumour busting' genes selectively to cancer cells, according to a study published online in Cancer Research.

11 Mar 2009

Metastatic bone disease patients can walk in Lazarus' footsteps

Osteoplasty - a highly effective minimally invasive procedure to treat the painful effects of metastatic bone disease by injecting bone cement to support weakened bones - provides immediate and substantial pain relief, often presenting individuals who are suffering terribly with the miraculous so-called "Lazarus effect," according to researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009

Drug therapy for brain tumors shows promise

The combination of two drugs produces a critical improvement in the treatment of certain brain tumours.

8 Mar 2009

Detailed diagnosis boosts child cancer survival

More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, according to research published in the Journal of Clinical Oncology.

5 Mar 2009

Serious flaws in study on vitamin C treatment in cancer

Serious flaws in a recent study, which concluded that high doses of vitamin C reduce the effectiveness of chemotherapeutic drugs in the treatment of cancer, are revealed in the current issue of Alternative and Complementary Therapies.

5 Mar 2009

Stem cell breakthrough gives new hope to sufferers of myopathy and muscular dystrophy

An experimental procedure that dramatically strengthens stem cells' ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases such as myopathy and muscular dystrophy, according to researchers from the University of New South Wales (UNSW).

5 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009